This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Malcolm Salter Biography and Net Worth

Director of C4 Therapeutics

Malcolm Salter has served as a member of the Board of Directors since December 2015. Malcolm is the James J. Hill Professor, Emeritus, at the Harvard Business School. Since joining the Harvard Business School faculty in 1967, his teaching and research has focused on issues of corporate strategy and governance. He currently serves on the boards of directors of NextRNA, Inc., a biotechnology company focused on developing the next generation of RNA-directed therapeutics, since February 2021, and Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since September 2020. From 1986 to 2006, he served as president of Mars & Co., a global strategy-consulting firm. He is a Trustee of the Dana-Farber Cancer Institute. Mr. Salter holds an A.B., M.B.A., and a D.B.A. from Harvard University.

What is Malcolm Salter's net worth?: The estimated net worth of Malcolm Salter is at least $55,371.60 as of August 20th, 2021. Mr. Salter owns 13,672 shares of C4 Therapeutics stock worth more than $55,372 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Salter may own. Learn More about Malcolm Salter's net worth.
How do I contact Malcolm Salter?: The corporate mailing address for Mr. Salter and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at [email protected]. Learn More on Malcolm Salter's contact information.
Has Malcolm Salter been buying or selling shares of C4 Therapeutics?: Malcolm Salter has not been actively trading shares of C4 Therapeutics during the last quarter. Most recently, Malcolm Salter sold 755 shares of the business's stock in a transaction on Friday, December 17th. The shares were sold at an average price of $30.25, for a transaction totalling $22,838.75. Learn More on Malcolm Salter's trading history.
Who are C4 Therapeutics' active insiders?: C4 Therapeutics' insider roster includes Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Malcolm Salter (Director), and Jolie Siegel (Insider). Learn More on C4 Therapeutics' active insiders.

Malcolm Salter Insider Trading History at C4 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2021	Sell	755	$30.25	$22,838.75
11/19/2021	Sell	755	$40.11	$30,283.05
10/15/2021	Sell	755	$44.94	$33,929.70
8/20/2021	Sell	755	$40.73	$30,751.15	13,672
7/16/2021	Sell	755	$37.37	$28,214.35	14,427
6/18/2021	Sell	755	$37.19	$28,078.45	14,843
5/21/2021	Sell	755	$37.12	$28,025.60	15,598

Malcolm Salter Buying and Selling Activity at C4 Therapeutics

C4 Therapeutics Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $4.05

$3.84

$4.23

50 Day Range

MA: $5.77

$4.05

$7.00

2 Week Range

Now: $4.05

$1.06

$11.88

Volume

1,298,082 shs

Average Volume

2,113,992 shs

Market Capitalization

$285.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.04

My #1 Pre IPO Trade for 2025 – NAME and TICKER

From Wyatt Investment Research | Ad

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

The Next SpaceX Pre-IPO